期刊文献+

维生素C在小剂量^(131)I治疗分化型甲状腺癌中的应用 被引量:1

Application of vitamin C in the treatment of differentiated thyroid cancer with low-dose ^(131)I irradiation
原文传递
导出
摘要 目的探讨维生素C对131I治疗分化型甲状腺癌发生放射性口腔炎或唾液腺炎的预防作用。方法 88例分化型甲状腺癌患者随机分为A组30例、B组32例与C组26例,3组均给予131I单次剂量30mCi治疗,A组于服药后2h,B组于服药后24h开始服用维生素C片10mg/次,3次/d,连续6d,2次治疗间隔3~6个月,C组服药后不用维生素C片;比较3组放射性口腔炎或唾液腺炎发生率。结果 A,B组放射性口腔炎或唾液腺炎发生率低于C组(P<0.05);A组与B组比较差异无统计学意义(P>0.05)。结论行131I治疗分化型甲状腺癌后2h和24h给予维生素C片均可有效降低放射性口腔炎或唾液腺炎的发生率。 Objective To assess the effect of vitamin C on the prevention of radiation stomatitis and salivoadenitis in patients with differentiated thyroid cancer treated with low-dose 131I (30 mCi) irradiation. Methods A total of 88 patients with differentiated thyriod cancer were randomly divided into group A (n=30), group B (n=32) and group C (n =26). All patients received 131I irraduation, 30 mCi for each time. Vitamin C was administered 2 hours later in group A and 24 hours later in group B, 10 mg per time, three times a day, for totally 6 days, with an interval time of three to six months between two treatments. Vitamin C was not administrated in group C. The incidences of radiation stomatitis and salivoadenitis were compared among three groups. Results The incidences of radiation stornatitis and salivoadenitis were higher in group A and B than those in group C (P(0.05), and there were no significant difference between group A and B (P〉0.05). Conclusion The use of vitamin C 2 hours or 24 hours later after being treated with low-dose 131I irradiation can effectively reduce the incidences of radiation stomatitis and salivoadenitis.
出处 《中华实用诊断与治疗杂志》 2012年第10期947-948,共2页 Journal of Chinese Practical Diagnosis and Therapy
基金 四川省卫生厅自然科学基金(080233)
关键词 分化型甲状腺癌 维生素C 131I治疗 Differentiated thyriod cancer vitamin C 131I irradiation
  • 相关文献

参考文献9

  • 1Walter M A, Turtschi C P, Schindler C, et al. The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study[J]. J Nucl Med, 2007,48(10) :1620-1625.
  • 2周久贸,李亚明.^(131)I治疗Graves甲状腺功能亢进的剂量制定[J].中华实用诊断与治疗杂志,2011,25(10):937-939. 被引量:4
  • 3青春,朱云芝,汪开明,蒙荣钦.小剂量^(131)I治疗24例肺转移性甲状腺癌临床分析[J].中华实用诊断与治疗杂志,2011,25(12):1169-1170. 被引量:8
  • 4Nakada K, Ishibashi T, Takei T, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer[J]. J Nucl Med,2005,46(2) :261-266.
  • 5Mandel S J, Mandel L. Radioactive iodine and the salivary glands[J]. Thyroid,2003,13(3) ,265-271.
  • 6Grewal R K, Larson S M, Pentlow C E, et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation[J]. J Nuel Med, 2009,50 (6): 1605- 1610.
  • 7汪开明,青春,朱芸芝.^(131)I治疗甲状腺机能亢进症的近远期疗效观察及早晚发甲状腺机能减退症因素分析[J].中华实用诊断与治疗杂志,2009,23(2):204-205. 被引量:12
  • 8Chow S M. Side effects of high-dose radioactive iodine for ablation or treatment of differentiated thyroid carcinoma[J]. J Hong Kong Coil Radiol, 2005,8(1) : 127-135.
  • 9Liu B, Kuang A, Huang R, et al. Influence of vitamin C on salivary absorbed dose of ^131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial [J]. J Nucl Med,2010,51(4) : 618-623.

二级参考文献34

  • 1余大富,吴晓群,魏明湘.小剂量^(131)I治疗甲亢224例分析[J].中国误诊学杂志,2007,7(2):308-309. 被引量:3
  • 2孔桂莲,马新峰.^(131)Ⅰ治疗甲亢的临床疗效观察[J].实用诊断与治疗杂志,2007,21(6):479-480. 被引量:3
  • 3Falk S A. Thyroid disease: Endocrinology, Surgery, Nuclear Medicine, and radiotherapy[ M ]. 2nd ed. Philadephia: Lippincott-Raven Publishers, 1997 : 241-252.
  • 4Bakker S C, Zanin D E, Zweers E J. Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose[J]. Ned Tijdschr Geneeskd,2002,146(39) :1837-1841.
  • 5Thientunyakit T, Thongmak S, Premprapha T. Comparative evaluation of two different dosage calculation protocols of iodine- 131 in the treatment of hyperthyroidism[J]. J Med Assoc Thai, 2010,93(8):969-977.
  • 6Ahmad A M, Ahmad M, Young E T. Objective estimates of the probability of developing hypothyroidism following radioactive iodine treatment of thyrotoxicosis[J]. Eur J Endocrinol,2002, 146(6) :767-775.
  • 7Howarth D, Epstein M, Lan L, et al. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study[J]. Eur J Nucl Med,2001,28 (10):1489-1495.
  • 8Grosso M, Traino A, Boni G, et al. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism[J]. Cancer Biother Radiopharm, 2005,20 (20) : 218-223.
  • 9Kita T, Yokoyama K, Kinuya S, etal. Single dose planning for radioiodine-131 therapy of Graves' disease[J]. Ann Nucl Med, 2004,18(2) :151-155.
  • 10DeGroot L J, Mangklabruks A, McCormick M. Comparison of RA ^131I treatment protocols for Graves' disease[J]. J Endocrinol Invest,1990,13(2) :111-118.

共引文献21

同被引文献9

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部